<DOC>
	<DOCNO>NCT00330317</DOCNO>
	<brief_summary>The aim study assess safety efficacy neoadjuvant hormone therapy letrozole postmenopausal woman estrogen- and/or progesterone-receptor positive primary breast cancer tumour regression permit breast conserve surgery .</brief_summary>
	<brief_title>Safety Efficacy Hormone Therapy With Letrozole Postmenopausal Women With Breast Cancer</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Hormones</mesh_term>
	<mesh_term>Letrozole</mesh_term>
	<criteria>1 . Postmenopausal woman able comply protocol requirement confirm primary invasive breast cancer whose tumour estrogenand/or progesteronereceptor positive 2 . Clinical stage T2 &gt; T2 tumours investigator ' opinion would eligible breastconserving surgery . The nodal status evaluate palpation and/or ultrasound . 3 . Postmenopausal status define one following : Women intact uterus AND ≥ 55 year age , OR &lt; 55 year age without menses last 5 year , OR &lt; 55 year age menses least last 12 month ( menses last 5 year ) postmenopausal level folliclestimulating hormone . Women without intact uterus AND ≥ 55 year age , OR &lt; 55 year age postmenopausal level folliclestimulating hormone Both ovaries remove ( prior diagnosis breast cancer ) . 4 . Tumour measurable clinical examination , mammography ultrasound 5 . Adequate bone marrow function show : WBC ≥ 3.5 x 10^9/L ANC ≥ 1.5 x 10^9/L Platelets ≥ LLN Hb &gt; 10 g/dL 1 . Multifocal disease ( cancer start several different site ) 2 . Patients bilateral breast tumour . 3 . Patients eligible breast conserving surgery . 4 . Evidence inflammatory breast cancer distant metastasis . 5 . Simultaneous anticancer treatment chemotherapy , immunotherapy/biological response modifier , endocrine therapy ( include steroid ) , bisphosphonate therapy radiotherapy . NOTE : Bisphosphonate therapy osteoporosis NOT exclude , continue . Patients receive hormone replacement therapy NOT exclude discontinue least 2 week start study . The following additional treatment NOT allow treatment phase study : Any anticancer therapy Hormone replacement therapy . Estrogen cream ( include intravaginal preparation ) . Steroids cream inhaler . Megestrol acetate treatment hot flush . Radiation therapy . Other protocoldefined inclusion/exclusion criterion may apply .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Letrozole</keyword>
	<keyword>Breast Conserving Surgery</keyword>
	<keyword>NeoAdjuvant</keyword>
	<keyword>Early Breast Cancer</keyword>
</DOC>